O	0	8	Efficacy
O	9	11	of
B-intervention	12	21	denosumab
O	22	25	for
O	26	35	restoring
O	36	42	normal
B-condition	43	47	bone
I-condition	48	55	mineral
I-condition	56	63	density
O	64	66	in
O	67	72	women
O	73	82	receiving
O	83	91	adjuvant
O	92	101	aromatase
O	102	112	inhibitors
O	113	116	for
O	117	122	early
O	123	129	breast
O	130	136	cancer
O	136	137	.

O	138	150	Osteoporosis
O	151	153	is
O	154	155	a
O	156	161	major
O	162	166	side
O	167	173	effect
O	174	176	of
O	177	186	aromatase
O	187	197	inhibitors
O	198	199	(
O	199	202	AIs
O	202	203	)
O	203	204	,
O	205	210	which
O	211	214	are
O	215	222	greatly
O	223	232	effective
O	233	235	in
O	236	239	the
O	240	249	treatment
O	250	252	of
O	253	259	breast
O	260	266	cancer
O	266	267	.

O	268	275	However
O	275	276	,
O	277	282	there
O	283	286	are
O	287	289	no
O	290	302	satisfactory
O	303	311	measures
O	312	319	against
O	320	332	osteoporosis
O	332	333	.

O	334	336	In
O	337	341	this
O	342	353	multicenter
O	353	354	,
O	355	365	randomized
O	365	366	,
O	367	378	comparative
O	379	384	study
O	384	385	,
O	386	388	we
O	389	397	evaluate
O	398	401	the
O	402	410	efficacy
O	411	413	of
O	414	423	denosumab
O	424	427	for
O	428	438	preventing
O	439	443	loss
O	444	446	of
O	447	451	bone
O	452	459	mineral
O	460	467	density
O	468	469	(
O	469	472	BMD
O	472	473	)
O	474	481	induced
O	482	484	by
O	485	493	adjuvant
O	494	501	therapy
O	502	506	with
O	507	509	AI
O	510	511	s
O	512	514	in
O	515	521	breast
O	522	528	cancer
O	529	537	patients
O	538	542	with
O	543	549	normal
O	550	553	BMD
O	553	554	.

O	555	558	The
O	559	563	bone
O	564	568	loss
O	568	569	-
O	569	580	suppressing
O	581	587	effect
O	588	590	of
O	591	600	denosumab
O	601	605	will
O	606	608	be
O	609	622	comparatively
O	623	632	evaluated
O	633	635	in
B-eligibility	636	650	postmenopausal
I-eligibility	651	659	patients
I-eligibility	660	669	scheduled
I-eligibility	670	672	to
I-eligibility	673	680	receive
I-eligibility	681	690	letrozole
I-eligibility	691	693	or
I-eligibility	694	705	anastrozole
I-eligibility	706	708	as
I-eligibility	709	710	a
I-eligibility	711	724	postoperative
I-eligibility	725	734	endocrine
I-eligibility	735	742	therapy
I-eligibility	743	746	for
I-eligibility	747	752	stage
I-eligibility	753	754	I
I-eligibility	754	755	-
I-eligibility	755	759	IIIA
I-eligibility	760	767	hormone
I-eligibility	767	768	-
I-eligibility	768	777	sensitive
I-eligibility	778	784	breast
I-eligibility	785	791	cancer
O	792	795	and
O	796	797	a
B-control	798	805	control
I-control	806	811	group
O	811	812	.

O	813	821	Patients
O	822	826	will
O	827	829	be
O	830	842	administered
O	843	852	letrozole
O	853	854	2
O	854	855	.
O	855	856	5
O	857	859	mg
O	860	862	or
O	863	874	anastrozole
O	875	876	1
O	877	879	mg
O	880	884	once
O	885	886	a
O	887	890	day
O	890	891	,
O	892	895	and
O	896	899	the
O	900	909	treatment
O	910	914	will
O	915	917	be
O	918	927	continued
O	928	931	for
O	932	933	5
O	934	939	years
O	940	946	unless
O	947	957	recurrence
O	957	958	,
O	959	968	secondary
O	969	975	cancer
O	975	976	,
O	977	979	or
O	980	992	unacceptable
O	993	1001	toxicity
O	1002	1010	develops
O	1010	1011	.

O	1012	1020	Patients
O	1021	1023	in
O	1024	1027	the
O	1028	1037	denosumab
O	1038	1043	group
O	1044	1048	will
O	1049	1056	receive
O	1057	1058	a
O	1059	1071	subcutaneous
O	1072	1081	injection
O	1082	1084	of
O	1085	1087	60
O	1088	1090	mg
O	1091	1093	of
O	1094	1103	denosumab
O	1104	1109	every
O	1110	1111	6
O	1112	1118	months
O	1118	1119	.

O	1120	1123	The
O	1124	1131	primary
O	1132	1140	endpoint
O	1141	1143	is
O	1144	1147	the
B-outcome-Measure	1148	1152	rate
I-outcome-Measure	1153	1155	of
I-outcome-Measure	1156	1162	change
I-outcome-Measure	1163	1165	in
I-outcome-Measure	1166	1169	the
I-outcome-Measure	1170	1176	lumbar
I-outcome-Measure	1177	1182	spine
I-outcome-Measure	1183	1184	(
I-outcome-Measure	1184	1186	L1
I-outcome-Measure	1186	1187	-
I-outcome-Measure	1187	1189	L4
I-outcome-Measure	1189	1190	)
I-outcome-Measure	1191	1194	BMD
O	1194	1195	,
O	1196	1198	as
O	1199	1209	determined
O	1210	1212	by
O	1213	1217	dual
O	1217	1218	-
O	1218	1224	energy
O	1225	1226	X
O	1226	1227	-
O	1227	1230	ray
O	1231	1245	absorptiometry
O	1246	1247	(
O	1247	1250	DXA
O	1250	1251	)
O	1251	1252	,
O	1253	1255	12
O	1256	1262	months
O	1263	1268	after
O	1269	1272	the
O	1273	1278	start
O	1279	1281	of
O	1282	1285	the
O	1286	1295	injection
O	1295	1296	.

O	1297	1300	The
O	1301	1310	secondary
O	1311	1320	endpoints
O	1321	1325	were
B-outcome-Measure	1326	1332	ETHICS
I-outcome-Measure	1333	1336	AND
I-outcome-Measure	1337	1350	DISSEMINATION
O	1350	1351	:
O	1351	1352	:
O	1353	1356	The
O	1357	1365	protocol
O	1366	1369	was
O	1370	1378	approved
O	1379	1381	by
O	1382	1385	the
O	1386	1399	institutional
O	1400	1406	review
O	1407	1413	boards
O	1414	1416	of
O	1417	1422	Kyoto
O	1423	1434	Prefectural
O	1435	1445	University
O	1446	1448	of
O	1449	1457	Medicine
O	1458	1461	and
O	1462	1465	all
O	1466	1469	the
O	1470	1483	participating
O	1484	1493	faculties
O	1493	1494	.

O	1495	1502	Written
O	1503	1511	informed
O	1512	1519	consent
O	1520	1523	was
O	1524	1532	obtained
O	1533	1537	from
O	1538	1541	all
O	1542	1550	patients
O	1551	1557	before
O	1558	1570	registration
O	1570	1571	,
O	1572	1574	in
O	1575	1585	accordance
O	1586	1590	with
O	1591	1594	the
O	1595	1606	Declaration
O	1607	1609	of
O	1610	1618	Helsinki
O	1618	1619	.

O	1620	1627	Results
O	1628	1630	of
O	1631	1634	the
O	1635	1640	study
O	1641	1645	will
O	1646	1648	be
O	1649	1661	disseminated
O	1662	1665	via
O	1666	1678	publications
O	1679	1681	in
O	1682	1686	peer
O	1686	1687	-
O	1687	1695	reviewed
O	1696	1704	journals
O	1704	1705	.

O	1706	1714	Clinical
O	1715	1721	Trials
O	1721	1722	.
O	1722	1725	gov
O	1726	1736	Identifier
O	1736	1737	:
O	1738	1749	NCT03324932
O	1749	1750	,
O	1751	1756	Japan
O	1757	1765	Registry
O	1766	1768	of
O	1769	1777	Clinical
O	1778	1783	Trial
O	1784	1785	(
O	1785	1789	jRCT
O	1789	1790	)
O	1790	1791	:
O	1792	1802	CRB5180001
O	1802	1803	.
